BIOMARKERS AND METHODS OF TREATING ASSOCIATED WITH PD-1 AND PD-L1 CONDITIONS Russian patent published in 2019 - IPC G01N33/574 C12Q1/68 

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, particularly to methods of selecting patients and predicting malignant disease. Method for identifying an individual with a malignant tumour, which is more likely to respond to treatment with a PD-L1-binding antagonist, involves: determining the presence or level of the PD-L1 biomarker in the sample from the individual, wherein by the presence or level of the PD-L1 biomarker in the sample, the individual is identified as likely to respond to the PD-L1 binding antagonist, and providing a recommendation that the individual will likely respond to the PD-L1-binding antagonist. Also disclosed are methods for determining the probability that an individual with a malignant tumour will benefit from treatment with a PD-L1-binding antagonist and methods of selecting a therapy for an individual with a malignant tumour. Also disclosed is a diagnostic kit for identifying an individual with a malignant tumour, which is likely to respond to the PD-L1-binding antagonist, containing one or more reagents for determining the presence or level of the PD-L1 biomarker in the sample from the individual with a malignant tumour, wherein the presence or level of PD-L1 biomarker indicates a probability of effectiveness in treating an individual with a PD-L1-binding antagonist.

EFFECT: group of inventions makes it possible to determine predictability of the therapeutic treatment by the PD-L1-binding antagonist of the existing malignant neoplasm in the patient.

174 cl, 30 dwg, 1 tbl, 20 ex